NeuroMab™ Anti-OPN BBB Shuttle Antibody(NRZP-1022-ZP2599)

Fig.1 shows the results of an examination of the bindability of chimeric 2K1 antibody and humanized 2K1 antibody to the hOPN5 peptide by an ELISA method.

The fig shows MAb inhibition of cell adhesion to OPN.

Fig.2 shows the cell adhesion inhibitory effects of R2K1v1.7 and R2K1v0 on human OPN.

The fig shows MAb inhibition of cell adhesion to OPN.

Fig.3 shows the effects of R2K1v1.7 on joint swelling in monkey collagen-induced arthritis.

The data are shown as mean±SE for 8 animals, 7 animals and 5 animals in the control group, 25 mg/kg group and 50 mg/kg group, respectively. *p<0.05, **p<0.01: significantly different from control group as determined by Dunnet's multiple comparison test.

Fig.4 shows the results of an examination of the bindability of purified R2K1v1.7-scFv to the hOPN5 peptide by an ELISA method.

The data are shown as mean±SE for 8 animals, 7 animals and 5 animals in the control group, 25 mg/kg group and 50 mg/kg group, respectively. *p<0.05, **p<0.01: significantly different from control group as determined by Dunnet's multiple comparison test.

Fig.5 shows the results of SDS-PAGE of the complete molecule type R2K1v1.7 antibody and the F (ab′)2 and purified F (ab′)2—PEG of the R2K1v1.7 antibody.

The data are shown as mean±SE for 8 animals, 7 animals and 5 animals in the control group, 25 mg/kg group and 50 mg/kg group, respectively. *p<0.05, **p<0.01: significantly different from control group as determined by Dunnet's multiple comparison test.

Fig.6 shows the results of an examination of the bindability of the F (ab′)2—PEG of R2K1v1.7 to the hOPN5 peptide by BIAcore.

The data are shown as mean±SE for 8 animals, 7 animals and 5 animals in the control group, 25 mg/kg group and 50 mg/kg group, respectively. *p<0.05, **p<0.01: significantly different from control group as determined by Dunnet's multiple comparison test.